AMRX Earnings
Latest Revenue796.2M
Latest Net Income69.6M
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q2 2026 | $0.18 | 796.2M | 69.6M | +9.9% | +157.1% |
| Q1 2026 | $0.20 | 722.5M | 78.0M | +3.9% | +400.0% |
| Q4 2025 | $0.11 | 814.3M | 49.6M | +11.5% | +210.0% |
| Q3 2025 | $0.01 | 784.5M | 18.1M | +11.7% | — |
| Q2 2025 | $0.07 | 724.5M | 35.6M | +3.2% | +250.0% |
| Q1 2025 | $0.04 | 695.4M | 24.6M | +5.5% | +113.3% |
| Q4 2024 | -$0.10 | 730.5M | -20742000 | +18.4% | +75.0% |
| Q3 2024 | $0.00 | 702.5M | 11.8M | +13.3% | -100.0% |
| Q2 2024 | $0.02 | 701.8M | 16.8M | — | — |
| Q1 2024 | -$0.30 | 659.2M | -81678000 | — | — |
| Q4 2023 | -$0.40 | 617.0M | -93344000 | — | — |
| Q3 2023 | $0.06 | 620.0M | 25.0M | — | — |
Amneal Pharmaceuticals (AMRX) — Earnings